Filana Therapeutics, Inc. Amortization of Intangible Assets
Filana Therapeutics, Inc. (FLNA) reported Amortization of Intangible Assets of $33.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-03-12
- Filana Therapeutics, Inc. amortization of intangible assets for the quarter ending 2024-12-31 was $32.00K, a 64.04% decline year-over-year.
- Filana Therapeutics, Inc. amortization of intangible assets for the quarter ending 2024-09-30 was $32.00K, a 73.11% decline year-over-year.
- Filana Therapeutics, Inc. amortization of intangible assets for the quarter ending 2024-06-30 was $56.00K, a 52.94% decline year-over-year.
- Filana Therapeutics, Inc. amortization of intangible assets for the quarter ending 2024-03-31 was $61.00K, a 48.74% decline year-over-year.
- Filana Therapeutics, Inc. amortization of intangible assets for fiscal 2025 was $33.00K, a 81.67% decline from fiscal 2024.
- Filana Therapeutics, Inc. amortization of intangible assets for fiscal 2024 was $180.00K, a 59.64% decline from fiscal 2023.
- Filana Therapeutics, Inc. amortization of intangible assets for fiscal 2023 was $446.00K, a 10.26% decline from fiscal 2022.
- Filana Therapeutics, Inc. amortization of intangible assets for fiscal 2022 was $497.00K, a 121.88% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $33.00K 10-K · filed 2026-03-12 | |||
| 2024-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $64.00K derived: sum of 2 quarters · filed 2026-03-12 | $120.00K derived: sum of 3 quarters · filed 2026-03-12 | $180.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $32.00K 10-Q · filed 2024-11-07 | $88.00K derived: sum of 2 quarters · filed 2024-11-07 | $148.00K 10-Q · filed 2024-11-07 | $238.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $56.00K 10-Q · filed 2024-08-08 | $117.00K 10-Q · filed 2024-08-08 | $206.00K derived: sum of 3 quarters · filed 2026-03-12 | $325.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $61.00K 10-Q · filed 2024-05-10 | $150.00K derived: sum of 2 quarters · filed 2026-03-12 | $269.00K derived: sum of 3 quarters · filed 2026-03-12 | $388.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $89.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $208.00K derived: sum of 2 quarters · filed 2026-03-12 | $327.00K derived: sum of 3 quarters · filed 2026-03-12 | $446.00K 10-K · filed 2026-03-12 |
| 2023-09-30 | $119.00K 10-Q · filed 2024-11-07 | $238.00K derived: sum of 2 quarters · filed 2024-11-07 | $357.00K 10-Q · filed 2024-11-07 | $475.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $119.00K 10-Q · filed 2024-08-08 | $238.00K 10-Q · filed 2024-08-08 | $356.00K derived: sum of 3 quarters · filed 2025-03-03 | $475.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $119.00K 10-Q · filed 2024-05-10 | $237.00K derived: sum of 2 quarters · filed 2025-03-03 | $356.00K derived: sum of 3 quarters · filed 2025-03-03 | $481.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $237.00K derived: sum of 2 quarters · filed 2025-03-03 | $362.00K derived: sum of 3 quarters · filed 2025-03-03 | $497.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $119.00K 10-Q · filed 2023-11-07 | $244.00K derived: sum of 2 quarters · filed 2023-11-07 | $379.00K 10-Q · filed 2023-11-07 | $513.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $125.00K 10-Q · filed 2023-08-03 | $260.00K 10-Q · filed 2023-08-03 | $394.00K derived: sum of 3 quarters · filed 2024-02-28 | $484.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $135.00K 10-Q · filed 2023-05-01 | $269.00K derived: sum of 2 quarters · filed 2024-02-28 | $359.00K derived: sum of 3 quarters · filed 2024-02-28 | $359.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $224.00K derived: sum of 2 quarters · filed 2024-02-28 | $224.00K derived: sum of 3 quarters · filed 2024-02-28 | $224.00K 10-K · filed 2024-02-28 |
| 2021-09-30 | $90.00K 10-Q · filed 2022-11-07 | $90.00K derived: sum of 2 quarters · filed 2022-11-07 | $90.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |